Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-arrestins and Venlafaxine Response in MDD
NCT02051413Phase 4Completed
- Sponsor
- Inserm
- Start
- Feb 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of venlafaxine in major depressive disorder (MDD), sponsored by Inserm. Primary endpoint: Hamilton Depression Rating Scale-17 items at 3 months. Started Feb 2014; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02051413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051413.